Helai P. Mohammad - Concepedia

Author

Helai P. Mohammad

Also Known As

H Mohammad, H P Mohammad, H. Mohammad, Hadhud Mohammad, Hazara Begum Mohammad, Helai P. Mohammad, Helai Mohammad, Helai P Mohammad, Helai P. Mohammad, Helai P. Mohammad

171

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Ghent University

About

Helai P. Mohammad is an author at GlaxoSmithKline (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	3.3K
2	Natural Sciences	4	4	1.6K
3	Engineering	1	1	29
4	Health Sciences	1	1	75
5	Biochemistry	1	1	62

Helai P. Mohammad

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing Joyce E. Ohm, Kelly M. McGarvey, Xiaobing Yu, Nature Genetics ChromatinHeritable SilencingChromatin StructureChromatin RemodelingMedicine	2007	1.1K
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat, Cancer Cell Oncogenic AgentMedicineEpigenetic ChangePharmacologyLsd1 Inhibitors	2015	498
Alterations of immune response of non-small cell lung cancer with Azacytidine John Wrangle, Wei Wang, Alexander Koch, Oncotarget	2013	382
Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island Heather M. O’Hagan, Helai P. Mohammad, Stephen B. Baylin PLoS Genetics Histone ModificationsSirt1-dependent OnsetDna Base OxidationGeneticsDna Methylation	2008	379
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien, Cancer Cell Cancer ResearchMtap LossMedicinePharmacologyCell Death	2019	333
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill, Nature Cancer Hematological MalignancyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaPharmacology	2021	251
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia Charles C. Bell, Katie Fennell, Yih-Chih Chan, Nature Communications	2019	175
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes Yi Cai, E-J Geutjes, Klaas de Lint, Oncogene GeneticsColorectal CancerNurd Complex CooperatesTumor SuppressorCancer Genetics	2013	126
DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes Eriko G. Clements, Helai P. Mohammad, Benjamin R. Leadem, Nucleic Acids Research	2012	121
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML Monica Cusan, Sheng F. Cai, Helai P. Mohammad, Blood	2018	115

Page 1